Home/Filings/4/0001062993-23-001385
4//SEC Filing

Rosenberger Brian 4

Accession 0001062993-23-001385

CIK 0001621443other

Filed

Jan 24, 7:00 PM ET

Accepted

Jan 25, 5:26 PM ET

Size

6.7 KB

Accession

0001062993-23-001385

Insider Transaction Report

Form 4
Period: 2023-01-23
Rosenberger Brian
VP, Commercial
Transactions
  • Sale

    Common Stock

    2023-01-23$0.60/sh12,663$7,57094,848 total
  • Award

    Common Stock

    2023-01-24+120,000214,848 total
Footnotes (2)
  • [F1]This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person.
  • [F2]The restricted stock award will fully vest in two installments, subject to continued employment with the Company through the applicable vesting date: 1/3 of the restricted stock will vest on February 1, 2024; and 2/3 of the restricted stock will vest on February 1, 2025.

Issuer

Zynerba Pharmaceuticals, Inc.

CIK 0001621443

Entity typeother

Related Parties

1
  • filerCIK 0001695788

Filing Metadata

Form type
4
Filed
Jan 24, 7:00 PM ET
Accepted
Jan 25, 5:26 PM ET
Size
6.7 KB